WB, IP, IHC-P, IF-IC
H M R Mk
Endogenous
25
Rabbit IgG
#O00264
10857
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
| Immunohistochemistry (Paraffin) | 1:200 |
| Immunofluorescence (Immunocytochemistry) | 1:100 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Mouse, Rat, Monkey
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human PGRMC1 protein.
Background
The progesterone receptor membrane component 1 (PGRMC1, Hpr6.6) was originally identified as a component of a progesterone-binding protein complex that also contains plasminogen activator inhibitor 1 RNA binding protein (PAIRBP1, SERBP1) (1,2). The structure of PGRMC1 protein includes a single transmembrane region and a carboxy-terminal cytochrome b5 heme-binding domain (3,4). Research studies confirm that PGRMC1 binds heme as well as binding and regulating cytochrome P450 enzymes responsible for the metabolism of clinical drugs and endogenous signaling molecules (5-7). While early research studies were equivocal on the ability of PGRMC1 to bind progesterone, studies using PGRMC1-fusion proteins clearly demonstrate that PGRMC1 binds progesterone with high affinity (2,8). Studies detailing expression of PGRMC1 in granulosa cells suggest that PGRMC1 mediates the anti-apoptotic actions of progesterone and that this protein is part of a signal transduction pathway that regulates granulosa cell function (9).
- Cahill, M.A. (2007) J Steroid Biochem Mol Biol 105, 16-36.
- Peluso, J.J. et al. (2008) Endocrinology 149, 534-43.
- Gerdes, D. et al. (1998) Biol Chem 379, 907-11.
- Mifsud, W. and Bateman, A. (2002) Genome Biol 3, RESEARCH0068.
- Crudden, G. et al. (2006) J Pharmacol Exp Ther 316, 448-55.
- Hughes, A.L. et al. (2007) Cell Metab 5, 143-9.
- Oda, S. et al. (2011) Drug Metab Dispos 39, 2057-65.
- Peluso, J.J. et al. (2009) J Clin Endocrinol Metab 94, 2644-9.
- Peluso, J.J. (2013) Front Neurosci 7, 99.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation IHC-P: Immunohistochemistry (Paraffin) IF-IC: Immunofluorescence (Immunocytochemistry)
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.